Loading patent…
AssigneeGITR, Inc.
InventorsL. Mary Smith, Grazyna Szymanska, Paul Ponath, Michael Rosenzweig, Jose F. Ponte
Estimating the term…
The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.
A method for inducing or enhancing an immune response in a subject, the method comprising administering to the subject an agonistic GITR (glucocorticoid-induced TNFR family-related receptor)-binding antibody, or an antigen-binding fragment thereof, such that an immune response or an enhanced immune response occurs, wherein said antibody or antigen-binding fragment thereof comprises the light chain complementarity determining region (CDR) amino acid sequences shown in amino acid residues 44-54 of SEQ ID NO:2, amino acid residues 70-76 of SEQ ID NO:2, and amino acid residues 109-117 of SEQ ID NO:2, and heavy chain CDR amino acid sequences shown in amino acid residues 45-56 of SEQ ID NO:1, amino acid residues 119-127 of SEQ ID NO:1, and one of amino acid residues 71-86 of SEQ ID NO:1 and amino acid residues 71-86 of SEQ ID NO:66.
The method of claim 1, wherein the antibody or antigen-binding fragment specifically binds glucocorticoid-induced TNFR family-related receptor (GITR) and competes for binding to GITR with the antibody or antigen-binding fragment of claim 1, 3, 9 or 24.
A method for inducing or enhancing an immune response in a subject, the method comprising administering to the subject an agonistic GITR (glucocorticoid-induced TNFR family-related receptor)-binding antibody, or an antigen-binding fragment thereof, and an antigen, such that an immune response or an enhanced immune response occurs, wherein said antibody or antigen-binding fragment thereof comprises the light chain complementarity determining region (CDR) amino acid sequences shown in amino acid residues 44-54 of SEQ ID NO:2, amino acid residues 70-76 of SEQ ID NO:2, and amino acid residues 109-117 of SEQ ID NO:2, and heavy chain CDR amino acid sequences shown in amino acid residues 45-56 of SEQ ID NO:1, amino acid residues 119-127 of SEQ ID NO:1, and one of amino acid residues 71-86 of SEQ ID NO:1 and amino acid residues 71-86 of SEQ ID NO:66.
A method for inducing or enhancing an immune response in a subject, the method comprising administering to the subject an agonistic GITR (glucocorticoid-induced TNFR family-related receptor)-binding antibody, or an antigen-binding fragment thereof, such that an immune response or an enhanced immune response occurs, wherein said antibody or antigen-binding fragment thereof comprises a humanized light chain amino acid sequence set forth in SEQ ID NO:
A method for inducing or enhancing an immune response in a subject, the method comprising administering to the subject an agonistic GITR (glucocorticoid-induced TNFR family-related receptor)-binding antibody such that an immune response or an enhanced immune response occurs, wherein said antibody consists of a humanized light chain amino acid sequence set forth in SEQ ID NO:
Dependencies are inferred from the claim text.